In this study, we employed ultrahigh performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) to analyze plasma metabolomic changes at three time points: before neoadjuvant chemotherapy (NAC), after the third cycle, and prior to surgery in patients with HER2-breast cancer receiving the TEC regimen. Here, ERBB2 is linked to breast cancer.